Seer logo

SeerNASDAQ: SEER

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

04 December 2020

Next earnings report:

08 August 2024

Last dividends:

N/A

Next dividends:

N/A
$106.50 M
-96%vs. 3y high
46%vs. sector
-vs. 3y high
-vs. sector
-94%vs. 3y high
21%vs. sector
-99%vs. 3y high
71%vs. sector

Price

after hours | Tue, 02 Jul 2024 20:00:10 GMT
$1.64-$0.09(-5.20%)

Dividend

No data over the past 3 years
$3.03 M$3.20 M
$3.03 M-$20.68 M

Analysts recommendations

Institutional Ownership

SEER Latest News

SEER RECEIVES CONTRACT FROM BIOCHAR NOW FOR THE MANUFACTURING OF KILNS AND INTENDS TO OPEN A JV TEXAS BIOCHAR FACILITY
globenewswire.com14 June 2024 Sentiment: -

SEER's product and manufacturing division, SEM, LLC, receives its first order from Biochar Now for the manufacturing of 33 kilns totaling approximately $600,000

Seer Proteographâ„¢ Provides Differentiated Insights into Spaceflight Proteomic Alterations for Precision Medicine and Biomarker Discovery
globenewswire.com11 June 2024 Sentiment: -

Secretome profiles from SpaceX Inspiration4 mission show alterations in oxidative stress, brain homeostasis, and coagulation

Seer, Inc. (SEER) Reports Q4 Loss, Tops Revenue Estimates
Zacks Investment Research29 February 2024 Sentiment: POSITIVE

Seer, Inc. (SEER) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $0.36 per share a year ago.

Here's Why Seer, Inc. (SEER) Could be Great Choice for a Bottom Fisher
Zacks Investment Research02 February 2024 Sentiment: POSITIVE

After losing some value lately, a hammer chart pattern has been formed for Seer, Inc. (SEER), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Seer to Present at the J.P. Morgan 42nd Annual Health Care Conference
GlobeNewsWire21 December 2023 Sentiment: POSITIVE

REDWOOD CITY, Calif., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will be participating in the upcoming J.P. Morgan 42nd Annual Health Care Conference in San Francisco, CA.

Seer to Present at the Canaccord MedTech, Diagnostics and Digital Health & Services Forum
GlobeNewsWire10 November 2023 Sentiment: NEUTRAL

REDWOOD CITY, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced company management will be participating in the upcoming Canaccord MedTech, Diagnostics and Digital Health and Services Forum in New York, NY.

Seer, Inc. (SEER) Q3 2023 Earnings Call Transcript
Seeking Alpha07 November 2023 Sentiment: POSITIVE

Seer, Inc. (NASDAQ:SEER ) Q3 2023 Results Conference Call November 7, 2023 4:30 PM ET Company Participants Carrie Mendivil - IR Omid Farokhzad - President, CEO David Horn - CFO Conference Call Participants Dan Brennan - TD Cowen Tejas Savant - Morgan Stanley Marta Nazarovets - JP Morgan Operator Good day, and thank you for standing by. Welcome to the Seer Third Quarter 2023 Earnings Conference Call.

Seer, Inc. (SEER) Reports Q3 Loss, Tops Revenue Estimates
Zacks Investment Research07 November 2023 Sentiment: POSITIVE

Seer, Inc. (SEER) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to loss of $0.38 per share a year ago.

Why Shares of Seer Are Slumping Wednesday
The Motley Fool09 August 2023 Sentiment: NEGATIVE

Seer CEO Omid Farokhzad said the company's sales are facing headwinds. The company lowered annual guidance for revenue.

Seer, Inc. (SEER) Reports Q2 Loss, Misses Revenue Estimates
Zacks Investment Research08 August 2023 Sentiment: NEGATIVE

Seer, Inc. (SEER) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to loss of $0.37 per share a year ago.

What type of business is Seer?

Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the secrets of the proteome. It develops Proteograph Product Suite, an integrated solution that comprises consumables, an automation instrumentation, and software that allows researchers to conduct proteomic studies in therapeutic and diagnostic research, and clinical trials. The company intends to sell its products for research purposes, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It has a collaboration agreement with Discovery Life Sciences, LLC. and the Salk Institute for Biological Studies. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.

What sector is Seer in?

Seer is in the Healthcare sector

What industry is Seer in?

Seer is in the Biotechnology industry

What country is Seer from?

Seer is headquartered in United States

When did Seer go public?

Seer initial public offering (IPO) was on 04 December 2020

What is Seer website?

https://seer.bio

Is Seer in the S&P 500?

No, Seer is not included in the S&P 500 index

Is Seer in the NASDAQ 100?

No, Seer is not included in the NASDAQ 100 index

Is Seer in the Dow Jones?

No, Seer is not included in the Dow Jones index

When does Seer report earnings?

The next expected earnings date for Seer is 08 August 2024